News & Videos - PREDILIFE - English

PRESS RELEASE MAY 29, 2024 . PREDILIFE STRENGTHENS ITS ASSETS WITH THE ISSUANCE OF A PATENT FOR ITS AI METHOD Villejuif, France - May 29, 2024 at 6:30 p.m. CET - PREDILIFE (Euronext Growth: ALPRE FR0010169920), a specialist in artificial intelligence methods for predicting disease risks for personalized medicine, is pleased to announce the issuance of a European patent by the European Patent Office for its risk prediction method for breast cancer used in the MammoRisk ® test. The breast cancer...

PRESS RELEASE MAY 1 st , 2024 . IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF €25.07 REPRESENTS +391% POTENTIAL UPSIDE Villejuif, France, May 1 st , 2024, 08:30 AM CET – PREDILIFE (Euronext Growth : ALPRE FR0010169920), a specialist in artificial intelligence methods for predicting the risk of pathologies for personalized medicine, announces the update of its target price by In Extenso Finance, an investment bank dedicated to small and medium-sized companies in...

PRESS RELEASE APRIL 25, 2024 . Valuation of MammoRisk ® software Villejuif, France (April 25, 2024) – PREDILIFE (Euronext Growth: ALPRE FR0010169920), a specialist in artificial intelligence methods for predicting the risk of pathologies for personalized medicine, announces the value of its MammoRisk ® software following an analysis by SORGEM Evaluation. PREDILIFE wanted to value the MammoRisk ® software to examine the possibility of licensing it to industrial partners and mandated SORGEM...